Brookline Capital Downgrades Verrica Pharmaceuticals to Hold
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has downgraded Verrica Pharmaceuticals from Buy to Hold, indicating a change in the analyst's outlook on the company's stock.
October 02, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Brookline Capital's analyst Kemp Dolliver has downgraded Verrica Pharmaceuticals from Buy to Hold, suggesting a more cautious outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less optimistic view on the stock's short-term performance, which could lead to a negative impact on the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100